Blackstone Inc
TVRD

Blackstone Inc’s Tvardi Therapeutics TVRD Stock Holding History

Blackstone Inc’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-674
Closed -$295K – 83
2015
Q2 		$295K Hold
674
– – ﹤0.01% 57
2015
Q1 		$244K Hold
674
– – ﹤0.01% 52
2014
Q4 		$242K Hold
674
– – ﹤0.01% 50
2014
Q3 		$203K Hold
674
– – ﹤0.01% 42
2014
Q2 		$413K Buy
+674
New +$363K ﹤0.01% 40

Other funds holding TVRD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

Blackstone Inc's TVRD Position: Q3 2015 in Review

Blackstone Inc sold out of Tvardi Therapeutics (TVRD) in Q3 2015, closing a stake of 674 shares — an estimated $295K sold.

Blackstone Inc first reported a position in TVRD in Q2 2014 and held it in 5 quarters. The position peaked at $413K in Q2 2014. 92 funds tracked by Wall St. Rank hold TVRD as of Q3 2015.

  • Blackstone Inc reported no remaining Tvardi Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Blackstone Inc sold 674 Tvardi Therapeutics shares in Q3 2015, an estimated $295K.
  • Blackstone Inc first reported a position in Tvardi Therapeutics in Q2 2014 and held it in 5 quarters.
  • Blackstone Inc's Tvardi Therapeutics position peaked at $413K in Q2 2014.
  • 92 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2015.

Based on Blackstone Inc's 13F filing for Q3 2015, filed 16 Nov 2015.